SCHEMBL13305146

SCHEMBL13305146

Cc1ccccc1-c1cc(-c2ccc3[nH]nc(C)c3c2)nc(=O)[nH]1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIM1 P11309 3/20 0.51
CDC7 O00311 10/20 0.50
GSK3B P49841 2/20 0.47
CSNK2A1 P68400 2/20 0.47
CSNK2A2 P19784 1/20 0.47
CLK1 P49759 1/20 0.47
CSNK2B P67870 1/20 0.47
CSNK2A3 Q8NEV1 1/20 0.47
CLK2 P49760 2/20 0.46
DYRK1A Q13627 2/20 0.46
MAPK13 O15264 1/20 0.46
DAPK3 O43293 1/20 0.46
ROCK2 O75116 1/20 0.46
PRKD3 O94806 1/20 0.46
MAP4K4 O95819 1/20 0.46
CDK1 P06493 1/20 0.46
FGFR1 P11362 1/20 0.46
RPS6KB1 P23443 1/20 0.46
CDK2 P24941 1/20 0.46
MAPK1 P28482 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5427424 0.87 CDC7 (0.61) PIM1CDC7GSK3BCSNK2A1CSNK2A2
SCHEMBL13329220 0.87 CDC7 (0.47) PIM1CDC7GSK3BCSNK2A1CSNK2A2
SCHEMBL3340582 0.86 PIM1 (0.41) PIM1CDC7GSK3BCSNK2A1CSNK2A2
SCHEMBL3339927 0.83 PIM1 (0.46) PIM1CDC7GSK3BCSNK2A1CSNK2A2
SCHEMBL3340464 0.82 PIM1 (0.43) PIM1CDC7GSK3BCSNK2A1CSNK2A2
SCHEMBL3340007 0.79 CDC7 (0.40) PIM1CDC7GSK3BCSNK2A1CSNK2A2
SCHEMBL3340730 0.79 PIM1 (0.43) PIM1CDC7GSK3BCSNK2A1CSNK2A2
SCHEMBL14547357 0.77 PIM1 (0.80) PIM1CDC7GSK3BCSNK2A1CSNK2A2
SCHEMBL3338793 0.76 PIM1 (0.50) PIM1CDC7GSK3BCSNK2A1CSNK2A2
SCHEMBL3340105 0.76 CDC7 (0.52) PIM1CDC7GSK3BCSNK2A1CLK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8324231-B2 Pyrimidinones as casein kinase II (CK2) modulators EXELIXIS, INC. (US) 2012-12-04 US disclosed
US-20100144770-A1 Pyrimidinones as Casein Kinase II (CK2) Modulators EXELIXIS, INC. (US) 2010-06-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100144770-A1 Pyrimidinones as Casein Kinase II (CK2) Modulators CSNK2A1, CSNK2A2, CSNK1A1 PIM1 579/4885CDC7 532/4885GSK3B 422/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.